Olaratumab Overview

Introduction of Olaratumab

Olaratumab (IMC-3G3) is a fully human IgG1κ monoclonal antibody developed by Eli Lilly and Company. It selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α. With the trade name Lartruvo, olaratumab has been approved by USA, Canada, and European Union to use in combination with doxorubicin for the treatment of adults with advanced soft-tissue sarcoma (STS) who cannot be cured by cancer surgery or radiation therapy, and who have not been previously treated with doxorubicin.

Mechanism of Action of Olaratumab

Platelet-derived growth factor (PDGF) and PDGFR together comprise the PDGF/PDGFR signaling axis, which plays a crucial role in the normal biological downstream cellular signaling required for organ development and function, in addition to promoting wound healing. Inadvertently, the PDGF/ PDGFR axis can promote autocrine growth stimulation of cancer cells. As a type of PDGFR, PDGFRα was found to be a receptor tyrosine kinase expressed in STS and its activation has been implicated in aberrant cell signaling leading to tumor growth and metastasis. As a PDGFRα antagonist, olaratumab binds to PDGFRα with high specificity and affinity, thereby, blocking PDGF-AA, PDGF-BB, and PDGFCC receptor activation and downstream signaling.

Fig.1 Mechanism of Action of Olaratumab

Clinical Projects of Olaratumab*

Approved Drugs of Olaratumab**

INN (trade name)	Therapeutic area	Dose	Strength	Route	Company	Marketing start	Market
Lartruvo	Soft tissue sarcoma (STS)	Injection, Solution	10 mg/mL	Intravenous	Eli Lilly and Company	October 19, 2016
Lartruvo	Soft tissue sarcoma (STS)	Injection, Solution	10 mg/mL	Intravenous	Eli Lilly Nederland B.V.	September 11, 2016
Lartruvo	Soft tissue sarcoma (STS)	Injection, Solution	10 mg/mL	Intravenous	Eli Lilly Canada Inc.	December 22, 2017

What We Provide

Therapeutic Antibody

Olaratumab

We provide high-quality Olaratumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Olaratumab

** Information presented in the table were collected from the following websites:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761038
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95790
https://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004216/human_med_002036.jsp

For research use only. Not intended for any clinical use.